Peran Kimia Medisinal dalam Pengembangan Terapi Thalasemia: Strategi Desain dan Optimalisasi Obat
DOI:
https://doi.org/10.31004/joecy.v5i2.162Keywords:
Thalasemia, Kimia Medisinal, Desain Obat, Terapi Chelating, Terapi GenetikAbstract
Thalasemia adalah kelainan genetik yang menyebabkan gangguan produksi hemoglobin, sehingga mengakibatkan anemia kronis dan komplikasi serius lainnya. Pengobatan utama saat ini melibatkan transfusi darah dan terapi chelating untuk mencegah penumpukan zat besi dalam tubuh. Namun, terapi ini memiliki keterbatasan, seperti efek samping dan ketergantungan seumur hidup. Kimia medisinal memainkan peran penting dalam pengembangan terapi yang lebih efektif dan spesifik untuk thalasemia, termasuk desain obat baru, optimalisasi senyawa chelating, serta pendekatan berbasis molekul kecil dan terapi genetik. Penelitian terkini berfokus pada strategi untuk meningkatkan bioavailabilitas obat, mengurangi toksisitas, dan mengembangkan terapi yang lebih personalisasi. Dengan pendekatan kimia medisinal yang inovatif, diharapkan pengobatan thalasemia dapat lebih efektif, aman, dan memberikan kualitas hidup yang lebih baik bagi pasien.
References
Atweh, G. F., & Schechter, A. N. (2017). Pharmacologic Induction Of Fetal Hemoglobin: Raising The Therapeutic Bar For The Treatment Of β-thalassemia And Sickle Cell Disease. Blood, 24(129), 3113–3120. https://doi.org/https://doi.org/10.1182/blood-2016-11-745711
Cappellini, M. D., & Motta, I. (2021). Advances In The Treatment Of Thalassemia. British Journal of Haematology, 1(192), 23–29. https://doi.org/https://doi.org/10.1111/bjh.17176
Fard, R. T., & Pourfarzad, F. (2018). Gene Therapy Approaches For β-Thalassemia: Recent Advances And Challenges. Trends in Molecular Medicine, 8(24), 720–731. https://doi.org/https://doi.org/10.1016/j.molmed.2018.05.003
Hossain, M. S., & Akter, S. (2022). Recent advances in drug design and medicinal chemistry approaches for β-thalassemia treatment. Medicinal Research Reviews, 3(42), 678–702. https://doi.org/https://doi.org/10.1002/med.21854
Modell, B., & Darlison, M. (2016). Global Epidemiology Of Hemoglobin Disorders And Derived Service Indicators. Bulletin of the World Health Organization, 6(86), 480–487. https://doi.org/https://doi.org/10.2471/BLT.06.036673
Nienhuis, A. W. (2017). Gene Therapy For The Hemoglobin Disorders: Past, Present, And Future. Blood, 7(129), 755–762. https://doi.org/https://doi.org/10.1182/blood-2016-09-692079
Rund, D., & Rachmilewitz, E. (2020). Beta-thalassemia. New England Journal of Medicine, 8(383), 729–743. https://doi.org/https://doi.org/10.1056/NEJMra1900196
Sankaran, V. G., & Weiss, M. J. (2021). Anemia: Progress In Molecular Mechanisms And Therapy. Nature Medicine, 8(27), 1334-1349. https://doi.org/https://doi.org/10.1038/s41591-021-01436-3
Sinha, S., & Karmakar, R. (2019). Emerging Therapies For β-Thalassemia: Molecular Targets And Novel Treatment Strategies. Expert Opinion on Investigational Drugs, 5(28), 419–432. https://doi.org/https://doi.org/10.1080/13543784.2019.1593152
Wang, W. C. (2019). Hydroxyurea Therapy For Thalassemia: Mechanisms And Clinical Implications. American Journal of Hematology, 1(94), 3–9. https://doi.org/https://doi.org/10.1002/ajh.25355
Weatherall, D. J. (2018). The Role Of Genomics In The Recognition, Diagnosis, And Management Of Hemoglobin Disorders. American Journal of Human Genetics, 4(104), 739–748. https://doi.org/https://doi.org/10.1016/j.ajh
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Saeful Amin, Naila Tazkyatun Naffsi, Nagita Cahya Ifana, Fauziah Harjakusuma
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
